Soleno Therapeutics, Inc

At Soleno, we are researching and developing medicines to treat rare genetic disorders, beginning with Prader-Willi syndrome (PWS), a life-threatening neurobehavioral, metabolic and endocrine disorder characterized by hyperphagia (insatiable hunger), neurocognitive and behavioral difficulties. Our lead candidate, DCCR, is a Phase 3, once-daily oral tablet under investigation as a potential treatment for PWS. Our priority is to bring the first approved treatment to patients to manage the most burdensome aspects of this devastating disorder

Biopharmaceuticals,therapeutics for the treatment of rare diseases,and pharmaceuticals

Soleno therapeutics, inc operates in the Pharmaceutical manufacturing industry.

Soleno therapeutics, inc's revenue is 11m - 100m

Soleno therapeutics, inc has 51 - 200 employees.